RVNC250117C2500
- 0.78
- 0.000.00%
Revance Therapeutics Newsroom
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Needham Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Hold Rating Issued Amid Acquisition Uncertainty for Revance Therapeutics
Revance Therapeutics Analyst Ratings
Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3
Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (RVNC) and Neurocrine (NBIX)
Revance Therapeutics Is Maintained at Neutral by Mizuho
Revance Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Revance Therapeutics (RVNC), Syndax Pharmaceuticals (SNDX) and Align Tech (ALGN)
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Announces Target Price $6.66
Needham Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Artivion (AORT) and Revance Therapeutics (RVNC)
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Barclays Remains a Hold on Revance Therapeutics (RVNC)
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Cautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties With Crown Laboratories
Stifel Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $6.66
Revance Therapeutics Analyst Ratings
H.C. Wainwright Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $6.6
Needham Maintains Revance Therapeutics(RVNC.US) With Hold Rating